Afficher la fiche abrégée

dc.contributor.authorWorld Health Assembly, 15
dc.coverage.spatialGenevaEN
dc.date.accessioned2014-10-05T17:08:07Z
dc.date.available2014-10-05T17:08:07Z
dc.date.issued1962
dc.identifier.govdocA15/P&B/WP/22
dc.identifier.govdocA15/P&B/WP/22 Rev.1
dc.identifier.urihttp://www.who.int/iris/handle/10665/135892
dc.description(‎Agenda item 2.2.3)‎EN
dc.language.isoenEN
dc.publisherWorld Health OrganizationEN
dc.subjectPharmaceutical productsEN
dc.subject.meshPharmaceutical PreparationsEN
dc.subject.meshDrug EvaluationEN
dc.subject.meshSubstance-Related DisordersEN
dc.titleNeeds of basic requirements for clinical evaluation of drugs and international exchange of information on their value and safety: amendment proposed by the Delegation of Austria to the resolution contained in Document A15/P&B/WP/17EN
dc.typeGoverning body documentsEN


Fichier(‎s)‎ constituant ce document

Thumbnail

Ce document figure dans la(‎les)‎ collection(‎s)‎ suivante(‎s)‎

Afficher la fiche abrégée